Antibody Drug Conjugates: Challenges & Future Perspectives

This presentation focuses on stromal-targeted antibody-drug conjugates (ADCs) as innovative approaches in oncology to address tumor heterogeneity. It explores Target-X and its prevalence in solid tumors, mechanisms of action through receptor modulation, and effects on angiogenesis by targeting cancer-associated fibroblasts. The development pipeline includes stringent selection criteria, target validation, and preclinical assays for efficacy and pharmacokinetics. Key findings highlight success...